Home » SURVIVING AS A STENT STARTUP
SURVIVING AS A STENT STARTUP
The medical device industry rarely sees an overnight success. But in April 2003,
when Johnson & Johnson first introduced the United States to a revolutionary
heart disease treatmenta drug-coated version of the stents commonly used
to prop open blocked arteries after they've been cleareddoctors jumped
at the opportunity and quickly opted for the newer products. In less than three
years, the global market for these drug-eluting stents has grown to $5.5 billion,
according to Hoovers, and Medtech Ventures expects it to reach $6.5 billion
in 2010. With an eye on the potential profits, ambitious startups are trying
to carve out a lucrative space by improving on the limitations of current stent
technology.
Red
Herring
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May